Source and scope
This summary is bounded to the recommendations, population and decisions covered by Post COVID-19 condition (long COVID): For health professionals. Apply it with the current provincial or territorial pathway where implementation differs.
sources for this section:PHAC post-COVID clinical guidance
Source-attributed clinical priorities
- Confirm a compatible post-COVID time course while investigating new, severe or alternative cardiopulmonary, neurologic and systemic diagnoses.
- Assess symptom burden, post-exertional exacerbation, cognition, sleep, autonomic symptoms, mental health and functional impact.
- Use individualized rehabilitation and pacing with goal-based follow-up; avoid a one-size-fits-all fixed exercise progression.
- New symptoms after infection still require assessment for unrelated and potentially treatable diagnoses.
sources for this section:PHAC post-COVID clinical guidance
Practical assessment and management workflow
1
Document infection timing, symptom clusters, exertional response, function, work and mental health.
2
Measure orthostatic observations, oxygenation and targeted cardiopulmonary or laboratory tests based on symptoms.
3
Agree on symptom-specific rehabilitation, pacing and treatment without forcing activity through post-exertional worsening.
4
Review trajectory and coordinate primary, rehabilitation and specialist services for persistent disability.
sources for this section:PHAC post-COVID clinical guidance
Safety, red flags and urgent escalation
- Escalate new chest pain, syncope, resting hypoxemia, focal neurology or severe psychiatric risk.
- Investigate pulmonary embolism, myocarditis or other acute disease when the presentation warrants it.
- Avoid promising an unproven drug or supplement as disease-modifying treatment.
sources for this section:PHAC post-COVID clinical guidance
Confirm the local pathway before acting
The evidence source is pan-Canadian, but formularies, funded access, referral routes, public-health directions and service availability remain provincial or territorial.
sources for this section:PHAC post-COVID clinical guidance
Source and implementation boundary
Read this educational summary with the linked source, current Canadian product information where medicines are involved, and the applicable provincial or territorial pathway. Local formularies, reporting duties, referral routes and service availability can differ.
sources for this section:PHAC post-COVID clinical guidance
Source documents
Use the linked source documents for complete recommendations, evidence grading, exclusions and implementation detail.
- Public Health Agency of CanadaPost COVID-19 condition (long COVID): For health professionalsCurrent federal clinical page checked 2026-08-20; links to the Canadian Guidelines for Post COVID-19 Condition 路 accessed 2026-08-20view source
continue the learning
From guidance to deliberate practice and evidence
Choose what happens next. iatroX can carry this page's jurisdiction, source-check date and released version into an editable learning record, support your reflection, or let you browse the regional question bank while keeping this topic visible. No action records completion, starts a session or awards CPD/CME credit automatically.
Add this guidance review to CPD/CMEOpen an editable learning-log record with this page鈥檚 provenance attached. You confirm the activity, time, reflection and mappings.Reflect on this with TutorUse optional prompts to consider what you learned and what鈥攊f anything鈥攜ou may change. Suggestions are never inserted automatically.Browse the Canada question bankKeep this guidance topic in view, then choose your exam and filters. No session starts automatically.
Found a source update or regional discrepancy? Tell the iatroX editorial team.